Oncolytics Biotech Successfully Raises $15M To Advance Breast And Pancreatic Cancer Clinical Programs
Portfolio Pulse from Happy Mohamed
Oncolytics Biotech Inc. (NASDAQ:ONCY) has successfully raised $15M in an underwritten public offering. The funds will be used to advance its clinical programs in metastatic breast and pancreatic cancers. The offering included 6,667,000 units at a price of $2.25 per unit, each consisting of one common share and one purchase warrant. The company also granted the underwriter an over-allotment option to purchase additional units, shares, or warrants up to 15% of the aggregate number of units sold.
August 08, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncolytics Biotech has raised $15M to fund its clinical programs. This could potentially lead to positive developments in their research, which may positively impact the company's stock.
The successful raising of funds indicates investor confidence in the company's ongoing research. This could lead to advancements in their clinical programs, potentially resulting in positive impacts on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100